ASCO, EORTC, ESMO, INCA and OECI endorse the 3rd WIN Symposium 6-8 July 2011

WIN Consortium, initiated by Cancer Institute Gustave Roussy (France) and University of Texas MD Anderson Cancer Center (USA), bringing together 17 academic centers worldwide, National Breast Cancer Foundation, Sage Bionetworks, and three industry partners Agilent technologies, GE Healthcare and Life technologies announces today that its 3rd WIN Symposium to be held in Paris 6 – 8 July has been endorsed by ASCO, EORTC, ESMO, INCA and OECI.

The extreme complexity of cancer raises medical, scientific, economic and societal challenges which require innovative medical and scientific approaches, as well as more efficient global cooperation. To this aim, outstanding leaders from worldwide pharma, biotech, academia and patient associations will present a unique forum to debate and focus on efficacy of cancer diagnostics and targeted therapeutics and to speed the process of translating discoveries to the benefit of the patient.

Why joining?

• A unique and innovative forum to debate efficacy of cancer diagnostics and therapeutics and to speed the process of translating discoveries to the benefit of the patient
• A unique opportunity to present your company and innovative technologies to global oncology leaders and to make business contacts
• Outstanding speakers from pharma, biotech and academia
• Very strong and innovative scientific program endorsed by ASCO, EORTC, OECI, INCA and ESMO (granted with 19 ESMO Mora category points).
• A chance to attend the WIN Consortium first workshops with its 22 member institutions coming from 5 continents including Agilent Technologies, Life Technologies and GE Healthcare.

An idea of the speakers:

Pharma and Biotech:

Mike Burgess, Robert Wasserman(Roche), Gary Gilliland (Merck and Co), Nick Botwood (AstraZeneca), Shannon Morris (GlaxoSmithKline), Samit Hirawat (Novartis), Antonella Isacchi and Arturo Galvani (Nerviano Medical Sciences), Paul Billings and Martin Naley (Life Technologies), Leo Bonilla (Agilent Technologies) and Ian Wilson (GE Healthcare).

Academia and patient organizations:

John Mendelsohn, Razelle Kurzrock and Donald Berry (UT-MDAnderson Cancer Center), Douglas Hanahan (ISREC), Samir Hanash (Fred Hutchinson Cancer Center), Leroy Hood (Institut for Systems Biology Seattle), David Sidransky (Johns Hopkins University), Stephen Friend (Sage Bionetworks), Keneth Anderson (Dana Farber Cancer Institute), Alexander Eggermont, Jean-Charles Soria (Institut Gustave Roussy), Janelle Hail (National Breast Cancer Foundation), Julio E. Celis (Danish Cancer Society), Denis Lacombe (EORTC), Robert Kerbel (Sunnybrook Health Sciences Center), Dominique Stoppa-Lyonnet (Institut Curie) , Soo Khee Chee ( National Cancer Centre, Singapore), Dingwey Ye (Fudan University Shanghai Cancer Center), and many others.

‘’We aim to create a forum for open discussion in which the expertise and input from all stakeholders in cancer drug development are crucial’’ said Dr. John Mendelsohn, Chairman of the WIN Consortium and President of the University of Texas MD Anderson Cancer Center.

“Focus of WIN Consortium and Symposium is to accelerate and increase access of patients to innovative clinical trials and treatments with the latest drugs. Your presence at this innovative event would be highly valuable” said Prof. Alexander Eggermont, Director of the Cancer Institute Gustave Roussy and Director of the WIN Consortium.

‘’A synthesis of the symposium, will be presented by Dr. Richard L. Schilsky, Chairman of the Scientific Advisory Board, aiming to present concrete perspectives to improve clinical outcomes and the quality of life of cancer patients worldwide” says Vladimir Lazar, WIN Chief Operating Officer.

Send your most innovative posters to share your science and technologies or chose to exhibit in this exceptional international environment.

Do not miss this network opportunity with oncology leaders from industry and academia.

Register now on http://www.winconsortium.org/symposium.html